Back
to sessions
Sep 29
Scientific
Credits
| AMA PRA Category 1 Credits: | 1.25 |
| CAMPEP Credits: | 1.25 |
| MDCB Credits: | 1.25 |
Presentations
-
02:15pm - 02:25pm ET
Primary and Retrospective Analysis of GRECO-2: A Randomized, Double-Blind, Placebo-Controlled Phase II Trial of SABR ± Rucosopasem in Localized Pancreatic Cancer
Speaker: Todd Aguilera, MD, PhD - UT Southwestern Medical Center, Dallas -
02:15pm - 03:30pm ETSpeaker: Jessica Frakes, MD - Moffitt Cancer Center, Tampa
-
02:15pm - 03:30pm ETSpeaker: Kyle Cuneo, MD - University of Michigan, Ann Arbor
-
02:25pm - 02:35pm ET
Stereotactic Body Radiation Therapy vs. Radiofrequency Ablation for Small (=2 cm) HCCs: Interim Results from a Prospective, Single-Center, Non-Inferiority Randomized Clinical Trial
Speaker: Lihong Wang, MD - The First affiliated Hospital Zhejiang University School of Medicine, Hangzhou -
02:35pm - 02:45pm ET
Prospective Study of Combined Stereotactic Body Radiotherapy and Immunotherapy in Locally Advanced Hepatocellular Carcinoma - Five-Year Survival Update
Speaker: Chi Leung Chiang, MD, MB, ChB - University of Hong Kong, Hong Kong -
02:45pm - 02:55pm ET
A Randomized Phase II Study of Hypofractionated Stereotactic Radiotherapy With Concurrent 5-fluorouracil /Capecitabine With or Without Zoledronic Acid in Locally Advanced Pancreatic Ductal Adenocarcinoma
Speaker: Chi Lin, MD, PhD, MS - University of Nebraska Medical Center, Omaha -
02:55pm - 03:05pm ET
Planning, Delivery and Safety of Dose-Escalated Radiation in GRECO2: Secondary Analysis of a Large International Randomized Trial for Localized Pancreatic Cancer
Speaker: Ryan Kuehnle, MD - UT Southwestern Medical Center, Dallas -
03:05pm - 03:15pm ET
Proton vs. Photon EBRT for Hepatocellular Carcinoma: A Multi-Institutional Individual Patient Data Analysis Using Propensity Score Weighting
Speaker: Ted Yanagihara, MD, PhD - University of North Carolina, Chapel Hill -
03:15pm - 03:25pm ETSpeaker: Michael Chuong, MD - Miami Cancer Institute at Baptist Health South Florida, Miami